Background: The use of
hemostatic agents is used to stop the bleeding. In medicine, an ideal
hemostatic agent should have been stop venous bleeding after being applied to
the lesion. This study investigated the
in vitro effects of A-Fact a hemostatic parameter. Methods: It has been determined in human plasma at different
rates. Hemostatic parameters were determined using routine biochemical methods. For
morphological evaluation in full blood, microscopic images of 5%, 10%, 15% and
50% drugs applied to blood samples were taken. Results: A-Fact
induced the very fast formation of protein network. Coagulation test was
performed on 2/20 dilution. The coagulation factor (II, VII, IX) was studied. The
levels of coagulation factors were not affected by A-Fact. Plasma fibrinogen
activities, total protein, albumin and globulin levels decreased, in parallel
and with the prolonged prothrombin time. And also INR values were increased
following the addition of the A-Fact. Conclusion: Our results suggested that the mechanism of A-Fact bleeding stopper has shown the formation of the
protein network. These data support that A-Fact may be evaluated as a new
hemostatic agent.Background: The use of
hemostatic agents is used to stop the bleeding. In medicine, an ideal
hemostatic agent should have been stop venous bleeding after being applied to
the lesion. This study investigated the
in vitro effects of A-Fact a hemostatic parameter. Methods: It has been determined in human plasma at different
rates. Hemostatic parameters were determined using routine biochemical methods. For
morphological evaluation in full blood, microscopic images of 5%, 10%, 15% and
50% drugs applied to blood samples were taken. Results: A-Fact
induced the very fast formation of protein network. Coagulation test was
performed on 2/20 dilution. The coagulation factor (II, VII, IX) was studied. The
levels of coagulation factors were not affected by A-Fact. Plasma fibrinogen
activities, total protein, albumin and globulin levels decreased, in parallel
and with the prolonged prothrombin time. And also INR values were increased
following the addition of the A-Fact. Conclusion: Our results suggested that the mechanism of A-Fact bleeding stopper has shown the formation of the
protein network. These data support that A-Fact may be evaluated as a new
hemostatic agent.
Amaç: Kanamayı
durdurmak için hemostatik ajanların kullanılır. Tıpta, ideal
bir hemostatik ajan lezyona uygulandıktan sonra venöz kanamayı durdurmalıdır. Bu
çalışmada A-Fact’ın hemostatik parametrelerinin invitro etkileri
araştırılacaktır. Yöntem: İnsan
plazmasında farklı oranlarda belirlenmiştir. Hemostatik parametreler rutin
biyokimyasal yöntemler kullanılarak belirlendi. Tam kanda morfolojik
değerlendirme için kan örneklerine% 5,% 10,% 15 ve% 50 ilaçların mikroskobik
görüntüleri alındı. Bulgular:
A-Fact,
protein ağının çok hızlı oluşumunu sağladı. Koagülasyon testi 2/20 seyreltme
üzerinde yapıldı. Koagülasyon faktörü 2,7 ve 9 çalışıldı ve A-Fact koagülasyon
faktörlerini etkilemedi. . Plazma fibrinojen aktivitesi, total protein, albümin
ve globulin düzeyleri azalırken buna paralel olarak protrombin zamanı uzadı.
Ayrıca,
A-Fact eklendikten sonra INR değerleri artırıldı. Sonuç: Sonuçlarımıza göre; A-Fact kanama durdurucunun mekanizması
protein ağı oluşumunu gösterdi. Elde edilen veriler A-fact’ı yeni bir
hemostatik ajan olarak gösterdi.
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Basic Science Research Articles |
Authors | |
Publication Date | December 29, 2018 |
Acceptance Date | December 16, 2018 |
Published in Issue | Year 2018Volume: 40 Issue: 4 |